Trial Profile

Ranibizumab for Edema of the mAcula in Diabetes: Protocol 3 With High Dose - the READ 3 Study.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Diabetic macular oedema
Focus Adverse reactions; Therapeutic Use
Acronyms READ-3

Most Recent Events

01 Oct 2021 Results of post hoc analysis assessing the differences in outcomes of subjects enrolled in the READ-3 study and evaluated the utility of various baseline parameters as predictors of outcomes at month 12, published in the Graefes Archive for Clinical and Experimental Ophthalmology.
06 Mar 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com